Skip to main content
Detailed chapter

CDH1 (Hereditary Diffuse Gastric Cancer)

E-cadherin, risk-reducing gastrectomy, and family planning

Pathogenic CDH1 germline variants raise hereditary diffuse gastric cancer (HDGC) risk and, in some families, lobular breast cancer risk. The gastric cancer page complements this page; decisions are not locked as “automatic surgery” without counseling.

CDH1

This figure shows: CDH1.

Key points

  • Who is offered evaluation?

    Multiple diffuse gastric cancers in a family, young-onset diffuse gastric cancer, CDH1-compatible lobular breast history, or a known family mutation are common triggers.

  • Surveillance vs surgery

    Key note inside

    Endoscopic surveillance has limits in diffuse disease. Risk-reducing total gastrectomy is individualized — not a single forced date for every carrier.

  • Breast risk and relatives

    Lobular breast risk may need intensified screening plans. Cascade testing for relatives runs through genetic counseling.

  • Important

    Key note inside

    This page is for education. It is not medical advice and does not replace a visit with your physician.

Frequently asked questions

  • Does endoscopy reliably catch early diffuse disease?

    Not always. That limitation is why risk-reducing total gastrectomy is discussed for some carriers.

  • Is there one mandatory surgery date?

    No. Timing depends on age, counseling, and shared decision-making.

This page is for education. It is not medical advice and does not replace a visit with your physician.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.